Literature DB >> 23071228

Comparative effectiveness research in oncology methodology: observational data.

Dawn L Hershman1, Jason D Wright.   

Abstract

The goal of comparative effectiveness research is to inform clinical decisions between alternate treatment strategies using data that reflect real patient populations and real-world clinical scenarios for the purpose of improving patient outcomes. Observational studies using population-based registry data are increasingly relied on to fill the information gaps created by lack of evidence from randomized controlled trials. Administrative data sets have many advantages, including large sample sizes, long-term follow-up, and inclusion of data on physician and systems characteristics as well as cost. In this review, we describe the characteristics of many of the commonly used population-based data sets and discuss the elements included within these data sets. An overview of common research themes that rely on population-based data and illustrative examples are presented. Finally, an overview of the analytic techniques commonly employed by health services researchers to limit the effects of selection bias and confounding is discussed. The analysis of well-designed studies of comparative effectiveness is complex. However, careful framing, appropriate study design, and application of sophisticated analytic techniques can improve the accuracy of nonrandomized studies. There are multiple areas where the unique characteristics of observational studies can inform medical decision making and health policy, and it is critical to appreciate the opportunities, strengths, and limitations of observational research.

Entities:  

Mesh:

Year:  2012        PMID: 23071228     DOI: 10.1200/JCO.2012.41.6701

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  48 in total

1.  Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer.

Authors:  Alex R Menter; Nikki M Carroll; Lori C Sakoda; Thomas Delate; Mark C Hornbrook; Rakesh K Jain; Lawrence H Kushi; Virginia P Quinn; Debra P Ritzwoller
Journal:  Clin Lung Cancer       Date:  2016-08-20       Impact factor: 4.785

2.  Use of Bevacizumab in Community Settings: Toxicity Profile and Risk of Hospitalization in Patients With Advanced Non-Small-Cell Lung Cancer.

Authors:  Nikki M Carroll; Thomas Delate; Alex Menter; Mark C Hornbrook; Lawrence Kushi; Erin J Aiello Bowles; Elizabeth T Loggers; Debra P Ritzwoller
Journal:  J Oncol Pract       Date:  2015-06-09       Impact factor: 3.840

3.  Improved systemic treatment for early breast cancer improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-year results from the Munich Cancer Registry.

Authors:  Dieter Hölzel; Renate Eckel; Ingo Bauerfeind; Bernd Baier; Thomas Beck; Michael Braun; Johannes Ettl; Ulrich Hamann; Marion Kiechle; Sven Mahner; Christian Schindlbeck; Johann de Waal; Nadia Harbeck; Jutta Engel
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-20       Impact factor: 4.553

4.  Clinical Benefits Associated With Medicaid Coverage Before Diagnosis of Gynecologic Cancers.

Authors:  Kemi M Doll; Ethan M Basch; Ke Meng; Emma L Barber; Paola A Gehrig; Wendy R Brewster; Anne-Marie Meyer
Journal:  J Oncol Pract       Date:  2016-05-31       Impact factor: 3.840

5.  Comparative effectiveness of adjunctive bevacizumab for advanced lung cancer: the cancer research network experience.

Authors:  Debra P Ritzwoller; Nikki M Carroll; Thomas Delate; Mark C Hornbrook; Lawrence Kushi; Erin J Aiello Bowles; Elizabeth T Loggers; Alex Menter
Journal:  J Thorac Oncol       Date:  2014-05       Impact factor: 15.609

6.  Level of hospital care and outcome of gastric cancer: a population-based evaluation of the Munich Cancer Registry.

Authors:  Anne Schlesinger-Raab; André L Mihaljevic; Silvia Egert; Rebecca T Emeny; Karl-Walter Jauch; Jörg Kleeff; Alexander Novotny; Natascha C Nüssler; Miriam Rottmann; Wolfgang Schepp; Wolfgang Schmitt; Gabriele Schubert-Fritschle; Bernhard Weber; Christoph Schuhmacher; Jutta Engel
Journal:  J Cancer Res Clin Oncol       Date:  2014-03-15       Impact factor: 4.553

7.  Characteristics and outcomes of reproductive-aged women with early-stage cervical cancer: trachelectomy vs hysterectomy.

Authors:  Hiroko Machida; Rachel S Mandelbaum; Mikio Mikami; Takayuki Enomoto; Yukio Sonoda; Brendan H Grubbs; Richard J Paulson; Lynda D Roman; Jason D Wright; Koji Matsuo
Journal:  Am J Obstet Gynecol       Date:  2018-08-21       Impact factor: 8.661

8.  Understanding Treatment Disconnect and Mortality Trends in Renal Cell Carcinoma Using Tumor Registry Data.

Authors:  Marc C Smaldone; Brian Egleston; John M Hollingsworth; Brent K Hollenbeck; David C Miller; Todd M Morgan; Simon P Kim; Aseem Malhotra; Elizabeth Handorf; Yu-Ning Wong; Robert G Uzzo; Alexander Kutikov
Journal:  Med Care       Date:  2017-04       Impact factor: 2.983

9.  Securing reimbursement for patient centered haemophilia care: major collaborative efforts are needed.

Authors:  Karin C Berger; Brian M Feldman; Joan Wasserman; Wolfgang Schramm; Victor Blanchette; Kathelijn Fischer
Journal:  Haematologica       Date:  2016-03       Impact factor: 9.941

10.  Referral patterns between high- and low-volume centers and associations with uterine cancer treatment and survival: a population-based study of Medicare, Medicaid, and privately insured women.

Authors:  Kemi M Doll; Ke Meng; Paola A Gehrig; Wendy R Brewster; Anne-Marie Meyer
Journal:  Am J Obstet Gynecol       Date:  2016-04-26       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.